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ABSTRACT
Identifying somatic mutations is critical for cancer genome characterization and for prioritizing patient treatment. DNA whole exome sequencing (DNAWES) is currently the most popular technology; however, this yields low sensitivity in low purity tumors.
RNA sequencing (RNA-seq) covers the expressed
exome with depth proportional to expression. We
hypothesized that integrating DNA-WES and RNAseq would enable superior mutation detection versus DNA-WES alone. We developed a first-of-itskind method, called UNCeqR, that detects somatic
mutations by integrating patient-matched RNA-seq
and DNA-WES. In simulation, the integrated DNA
and RNA model outperformed the DNA-WES only
model. Validation by patient-matched whole genome
sequencing demonstrated superior performance of
the integrated model over DNA-WES only models, including a published method and published mutation
profiles. Genome-wide mutational analysis of breast
and lung cancer cohorts (n = 871) revealed remarkable tumor genomics properties. Low purity tumors
experienced the largest gains in mutation detection
by integrating RNA-seq and DNA-WES. RNA provided
greater mutation signal than DNA in expressed mutations. Compared to earlier studies on this cohort,
UNCeqR increased mutation rates of driver and therapeutically targeted genes (e.g. PIK3CA, ERBB2 and

FGFR2). In summary, integrating RNA-seq with DNAWES increases mutation detection performance, especially for low purity tumors.
INTRODUCTION
Somatically acquired sequence mutations (nucleotide substitutions, insertions and deletions) fuel the initiation and
progression of cancer (1). Knowledge of mutations in patient specimens informs therapeutic management (2,3), and
in large patient cohorts, provides the basis to assess recurrently altered genes that may drive molecular pathogenesis
(1,4–5). DNA whole exome sequencing (DNA-WES) is currently the popular technology to sequence cancer genomes
and has led to an abundance of discoveries in many cancer types (4,6–8). However, detecting somatic mutations by
DNA-WES with high sensitivity and specificity remains a
challenge (7,9–10), as evidenced by validation rates of 73%
in repeated sequencing and by large inter-rater disagreement among different groups analyzing the same sequencing data (7,10). The biggest challenge is high quality mutation detection in low purity tumors (2,9,11), which are
prevalent in widespread cancer types such as breast and
lung (12). Advances in somatic mutation detection could
improve cancer genome characterization and lead to new
diagnostic and therapeutic targets.
Somatic mutation detection is dependent on tumor features, the sequencing technology, and the method of statistical modeling (8–9,13–17). To detect somatic mutations, algorithms compare tumor and patient-matched germline sequencing based on a variety of models (4,6–7,9,13–17). A
tumor’s degree of normal contamination and clonal hetero-
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MATERIALS AND METHODS
Data sources
DNA-WES and RNA-seq alignments in BAM (31) format for 176 lung squamous cell carcinoma cases and for
695 breast cancer cases were acquired from TCGA at
https://cghub.ucsc.edu (Supplementary Table S1). RNAseq were paired 50 nt read from Illumina HiSeq, aligned by
MapSplice (4,32). DNA-WES were paired 76–100 nt reads
from Illumina Genome Analyzer, aligned by BWA (33).
All lung and breast cancer cases had germline DNA-WES,

tumor DNA-WES and tumor RNA-seq and were referred
to as the triplet cohorts. A subset of 12 lung and 91 breast
tumors also had germline RNA-seq available and were
referred to as the quadruplet cohorts. DNA whole genome
sequencing (DNA-WGS) was acquired from TCGA for
tumors in this cohort (breast: n = 43, lung: n = 17), which
consisted of BWA alignments of paired 100 nt reads. Exonic
coordinates were extracted from the TCGA Genome Annotation File (http://tcga-data.nci.nih.gov/docs/GAF/GAF.
hg19.June2011.bundle/outputs/TCGA.hg19.June2011.gaf)
and padded with 10 flanking positions, for a total of 222 055 exons. Published mutations (lung:
breast:
LUSC Paper v8.aggregated.tcga.somatic.maf,
genome.wustl.edu BRCA.IlluminaGA DNASeq.Level 2.
5.1.0.somatic.maf), expression subtypes, DNA copy number calls and tumor purity calls (12) were obtained when
available from TCGA. Numerical purity calls of 1 with an
incongruent ‘Low purity’ categorical call were censored.
Sequencing quality filtering
The high quality data filter applies to alignments and genomic positions, similar to earlier studies (9,14). High quality sequenced bases from tumor alignments had base quality ≥20 and occurred in a parent alignment with the following properties: mapping quality ≥ 20, sum of reference
mismatches insertions and deletions ≤2, a proper pair orientation, not a marked duplicate or qc-failure, not within
the terminal two bases, and the singular best alignment.
All bases from germline alignments were accepted. High
quality genomic positions were those with germline depth
≥10, tumor high quality depth ≥5 in RNA or DNA, no
homopolymer > 4 on either side of the site, proportion of
high quality bases ≥0.25 in RNA or DNA, and without an
insertion or deletion event at 10% allele fraction within 50
positions in germline sequencing. The high quality data filter was applied prior to detecting to tumor variant alleles.
The high quality variant filter passes DNA or RNA variant
alleles without significant strand bias compared to germline
alleles (chi-square P < 0.01), with at least one read on both
strands for indel variants, with major variant allele prevalence (the proportion of major variant reads out of all variant reads) ≥0.75, and a MAD of distance to the end of its
aligned read sequence ≥1.
Somatic mutation detection
The UNCeqR algorithm detected somatic mutations within
exons based on input of tumor and patient-matched
germline sequence alignments. The algorithm applied the
following steps to each genomic site within exons:
(1) filter for high quality data;
(2) identify germline alleles from germline reads that have
at least 2% allele prevalence;
(i) add population polymorphisms and mapping artifact alleles to germline alleles (see following section ‘Population polymorphisms and mapping artifacts’).
(3) Using tumor sequences:
(i) let g be the number of reads matching germline alleles,
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geneity decrease tumor purity. Low purity affects the fraction of mutated DNA observed out of all DNA at a genomic
site, the mutant allele fraction (MAF) (8,12). MAF is not often 100%, can be slightly above zero in low purity tumors,
and varies across the genome depending on the prevalence
of clones possessing a given mutation and on copy number
alterations (7,9,12). DNA-WES targets roughly 200 000 exonic regions and, in practice, can yield depths of 100X or
greater over targeted regions (4,6). DNA-WES has limitations including variable capture-efficiency and incomplete
exome coverage (7,18). In cases of high MAF, mutation detection is straightforward as only a small number of reads
are needed to detect the mutation with confidence. The combination of low depth and low MAF make mutation detection very difficult because of low statistical power, a result
of the scant sample size in which to observe and detect the
low prevalence mutation.
Increased mutation detection sensitivity and specificity
could be achieved by statistical improvements, by increasing sequencing quantity or by increasing sequencing quality. In cancer profiling projects such as The Cancer Genome
Atlas (TCGA) (4,6) and in clinical sequencing (2,19), DNAWES is utilized for mutation detection while RNA sequencing (RNA-seq) (20) is performed for gene expression, fusion
transcript and splicing analyses. Beyond those applications,
RNA-seq provides an observation of the underlying tumor
DNA sequence, via transcription, and can be used to detect sequence variants (21). In fact, we have previously used
RNA-seq to confirm mutations from DNA-WES (4). A few
earlier studies have used RNA-seq alone for genome-wide
identification of somatic mutations (22–25) and germline
variants (26,27). However, RNA-seq has challenges including dependency on gene expression, which limits the genes
that can be measured for sequence mutations, and quality control requirements, which when not considered result
in abundant false positive variants (11,21,28–30). For these
reasons, RNA-seq has not been the standard for somatic
mutation detection.
Herein, we posed the original hypothesis that integrating patient-matched tumor RNA-seq and tumor DNAWES would enable superior mutation detection versus
DNA-WES alone. We developed a first-of-its-kind method,
UNCeqR, that simultaneously analyzes DNA-WES and
patient-matched RNA-seq to detect somatic mutations
genome-wide. UNCeqR was applied to large breast and lung
cancer cohorts and evaluated with respect to simulation
and whole genome sequencing validation. Subsequently,
genome-wide analysis of UNCeqR mutations led to novel
discoveries in tumor genomics.
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A set of mutation detection models applied the algorithm
with different inputs and statistical models. UNCeqRDNA
takes tumor DNA-WES as input and models the corresponding read counts by a beta-binomial distribution. For
a variant site with read count kDNA , the P-value to assess
whether this variant allele is a somatic mutation was calculated by
PDNA = 1 −

k−1 

n
i =0


DNA

i

B (i + αDNA , n DNA − i + βDNA )
,
B(αDNA , βDNA )

where B is the beta function, and α DNA and β DNA are parameters of the null distribution where the variant allele is
not a somatic mutation. Specifically, α DNA and β DNA are
estimated using randomly sampled sites until 50 000 have
passed the high quality data filter in both tumor DNAWES and tumor RNA-seq. In real data analysis, these sampled sites may include real somatic mutations and thus the
estimates of α and β are conservative, which may lead to
conservative P-value estimates. However, based on mutation rates reported in prior studies (8 mutations per 1 000
000 sites (4)), less than one mutation is expected in these
sampled sites, and thus our estimates of α and β would be
good approximations of the estimates from a set of nonsomatic mutation sites. The UNCeqRRNA model is identical to UNCeqRDNA substituting tumor RNA-seq for tumor DNA-WES. The UNCeqRMETA model combines Pvalues from UNCeqRDNA and UNCeqRRNA if RNA and
DNA have the same major variant allele irrespective of filtering; otherwise the UNCeqRMETA P-value is set to that
of UNCeqRDNA . In effect, this condition precludes sites
with only RNA variant evidence, that are suggestive of
RNA-editing (34,35), from being called somatic mutations.
UNCeqRMETA combines P-values by the Stouffer method
(36–38) with weights of the root of their sample size (read
depth at the site) as follows:
PMETA = 1 −


√
√
Φ −1 (1 − PDNA ) n DNA + Φ −1 (1 − PRNA ) n RNA

Φ
,
n DNA + n RNA
−1

where Φ is the standard normal cdf and Φ is the inverse
of Φ, i.e. the quantile function of the standard normal dis-

tribution. If the RNA major variant equals the DNA major variant and PDNA = NA, PMETA is set to PRNA . DNA
and RNA variant read counts among putative false positives were unassociated supporting the usage of Stouffer’s
method (Supplementary Figure S1). Due to possible ambiguity around insertions and deletions (‘indels’) between
DNA and RNA alignments, high quality variant sites with
an insertion or deletion major variant allele in one alignment and with the same variant allele (insertion or deletion)
occurring within 20 sites as the major variant allele in the
other alignment were merged to have the same genomic position prior to statistical testing. This indel merge allowed
indel variants sites between DNA and RNA that represent
the same variant, to be recorded at the same site and allowed
UNCeqRMETA to combine this DNA and RNA evidence despite slightly different representation in the sequence alignments. UNCeqR software consisted of modified samtools
(31), Perl, R and VGAM (39). The total number of applied
statistical tests is reported in UNCeqR output to provide interested users the possibility of multiple testing adjustment.
Population polymorphisms and mapping artifacts
Population-level polymorphisms were acquired from dbSNP common version 137 via the UCSC genome browser
(40). Variant alleles caused by ambiguous mapping artifacts
were calculated by BlackOps (41) using 2 × 50 paired-end
reads aligned by MapSplice. UNCeqR was applied to 45
TCGA RNA-seq of matched normal tissue specimens (not
part of the lung or breast cohorts) to detect non-reference
sequence variants, representing further germline polymorphic and alignment artifact alleles. These alleles always augmented germline genotype in UNCeqR, thus preventing somatic mutation detections with these alleles even if unobserved in a given germline sequencing.
Mutation annotation and analysis
Sequence mutations were annotated with a gene, a predicted
transcript and protein alteration using Annovar (version
8/23/13) (42) and RefSeq gene models. Non-silent mutations referred to non-silent substitution, insertion and deletion mutations within translated regions and splice-site mutations. MAFs were compared by one-sided Fisher’s exact
tests on mutant versus germline read counts with significant results having false discovery rate < 5%. Sequence
alignments were visualized using the Integrative Genomics
Viewer (43).
Germline variant analysis
Patient germline variants relative to the reference genome
were detected in germline DNA-WES and patient-matched
germline RNA-seq using UNCeqRMETA without population polymorphism or mapping artifact allele augmentation, P ≤ 1.1e−9. Germline variant allele fractions were
defined and compared between DNA and RNA, using the
procedure described for somatic mutations.
Simulation analysis
A novel simulation strategy was followed (diagrammed in
Supplementary Figure S2). Using chromosome 2, simulated
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(ii) determine most frequent allele, that does not match
germline alleles,
(iii) let k be the number of reads with this major variant
allele,
(iv) let n = k + g.
(4) If major variant allele is insertion or deletion, re-align
nearby indel alleles:
(i) scan 20 neighboring sites to find site s with maximum k and same major variant allele,
(ii) if current site is not s.
1. Move major variant read count from current site
to s by incrementing k at s and decrementing g
at s by current site’s major variant read count.
2. Continue to next site.
(5) If high quality variant filter is passed, apply statistical
test, otherwise P = 1 if k = 0, else P = NA..
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Mutation detection by other programs
Strelka v2.0.8 (17) was executed on tumor and germline
DNA-WES using recommended settings for BWA alignments (strelka config bwa default.ini), DNA-WES (isSkipDepthFilter = 1) and filtering (passed). SNVMix2 (13)
was executed upon RNA-seq using default settings.
Validation analysis
Within exonic regions, true positive and false positive mutation detections were defined using patient-matched DNAWGS alignments based on a published procedure for exome
mutation validation (4). Tumor and germline DNA-WGS
BAM files were downloaded from https://cghub.ucsc.edu.
Specifically, tumor and germline DNA-WGS were interrogated at each predicted mutation using samtools (31) with
no filtering. True positive mutation predictions met one of
two conditions: (1) germline depth ≥ 10 and read count of
predicted mutant allele ≥1 in tumor and zero in germline;
or (2) germline depth ≥10, proportion of mutant allele in
germline sequencing not significantly > 2% (proportions
test, P > 0.25) and proportion of mutant allele in tumor
significantly greater than in germline (proportions test, P
< 0.05). Otherwise, false positive mutation predictions had
germline DNA-WGS depth ≥10, and had depth in tumor
DNA-WGS providing ≥80% power to detect the mutant

allele based the predicted MAF. Power was estimated by a
binomial distribution, a null probability of 3 × 10−3 , an alpha of 0.05, the observed depth in DNA-WGS and an alternate probability of the predicted DNA MAF. The number of true positives and false positives were tabulated at
each model discrimination threshold, i.e. P-value or score.
The step function of these points (number of false positives
versus number of true positives) generated a performance
curve in absolute counts that is equivalent to a ROC curve
without the denominators of total positives and negatives,
which were constant and unknown for the validation cohort. Between models, performance curves were compared
by area under the curve from 0 to 3000 false positives and
by the number of true positives (proportional to sensitivity) at fixed numbers of false positives (proportional to 1 −
specificities) of 250, 500 and 1000). P-values were calculated
to provide evidence for the change in area under the curve
and sensitivity estimates using permutation (see ‘Simulation
analysis’ methods).
RESULTS
Mutation detection models
Existing methods to detect somatic mutations are based
on either DNA sequencing alone or on RNA sequencing
alone and do not integrate more than one type of sequencing (9,13–17). In order to test whether integrating DNAWES and RNA-seq enables superior somatic mutation detection versus the current standard of DNA-WES alone,
a new method was developed, called UNCeqR. UNCeqR
contains different models for detecting somatic mutations
based on different sequencing input and statistical modeling. Briefly, UNCeqRMETA integrates tumor DNA-WES
and RNA-seq, UNCeqRDNA uses tumor DNA-WES, and
UNCeqRRNA uses tumor RNA-seq. UNCeqR software is
available at http://lbg.med.unc.edu/tools/unceqr.
Evaluation in simulated tumor sequencing
To test our hypothesis that somatic mutation detection
based on integrated RNA-seq and DNA-WES is superior to
that based on DNA-WES alone, simulated tumor genomes
were generated so that the entire genome space is a completely defined truth of positive and negative somatic mutations. In brief, for each patient’s sequencing, 500 mutant
sites were sampled, for each site a mutant allele was randomly sampled, and then aligned reads in the real RNAseq and DNA-WES were edited to have the mutant allele at
a rate of a fixed MAF (Supplementary Figure S2). By using real sequencing as the basis of the simulation, authentic
sequencing depths, random errors (sequencing and alignment) and patients’ germline variants were preserved.
Sequencing from the lung cancer quadruplet cohort was
used for simulation. Patients’ DNA-WES and RNA-seq
had large and similar numbers of sequenced nucleotides
(DNA-WES median: 10.6 billion, RNA-seq median: 10.2
billion; Kruskal-Wallis P = 0.54) indicating no significant
imbalance in total sequencing. UNCeqR models were applied to the simulated tumor sequencing and detected mutations were compared against the truth by receiver operating
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tumor genomes were generated by randomly sampling 500
sites from exons to define positive mutation sites while the
remainder of exon sites served as negative mutations. For
the positive sites, mutant alleles (substitution, insertion or
deletion) were randomly sampled at rates 90, 5 and 5%.
For insertion and deletion alleles, allele lengths of 1–6 were
randomly sampled at rates 60, 20, 9, 5, 5 and 1%. Positive mutations were spiked into germline DNA-WES and
RNA-seq sequencing by editing a specified MAF of read
alignments overlapping the site, producing simulated tumor
alignments. ‘V’ characters were used for substitutions and
insertions to avoid overlap with germline genotype. Simulated tumor alignments contained a subset of the total
positive mutations because the alignment may have minimal or zero depth at some positive sites, reflecting reality
that a sequencing technology does not cover every site in
the genome at high depth and enabling simulated mutations to occur at RNA-seq and DNA-WES uniquely covered sites. Original tumor sequencing served as simulated
germline sequencing. Simulated germline sequencing contained the original somatic mutations, which had the effects
of expanding germline genotype with additional alleles and
not triggering variant detection. UNCeqR models were applied to these simulated data. Limiting to sites with at least
a germline depth of 10, model detections were compared to
the truth to define receiver operating characteristic (ROC)
curves (44). A pair of models was compared by their difference in area under the curve over the false positive rate
range of 0 to 1 × 10−5 . A P-value was defined using a distribution of differences in area under the curve calculated
from 100 permuted models in which the rank of the discrimination threshold (i.e. P-value) between the models at each
genomic site was randomly shuffled.
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Validation by whole genome sequencing

Figure 1. Mutation detection performance in simulated tumor genomes.
Model performance is displayed as receiver operating characteristic curves.
Sensitivity plateaus below 1 because simulated mutations include sites with
zero tumor sequencing depth in DNA and/or RNA (see ‘Simulation analysis’ methods).

characteristic curves. In simulations with a 10% MAF (Figure 1A), the UNCeqRMETA model had significantly superior

To validate the superior performance of integrated DNAWES and RNA-seq mutation detection (UNCeqRMETA )
over DNA-WES only detection (UNCeqRDNA ), tumor and
germline whole genome DNA sequencing (DNA-WGS)
was used as an independent measure of truth for evaluating DNA-WES and RNA-seq mutation detections. Following a published validation procedure (4), mutation detections were interrogated in patient-matched DNA-WGS
to determine if a mutation detection was a true positive,
that is present in the tumor specimen and absent from the
germline specimen, or false positive, that is absent from
the tumor specimen or present in the germline specimen.
For each mutation model, true positives and false positives were summed at each discrimination threshold (e.g.
P-value) to generate a performance curve by which true
positive rates could be compared at the same false positive rates (see methods for further description). These curves
demonstrated that UNCeqRMETA achieved overall superior
performance than UNCeqRDNA (difference in area under
the curve, P < 0.01) and at fixed false positive thresholds
(250, 500 and 1000), thus, validating the result from simulated tumor genomes (Figure 2). Therefore, in real tumor
sequencing, integrated DNA and RNA mutation detection
by UNCeqRMETA outperformed DNA-only mutation detection.
Other models displayed overall reduced performance
relative to UNCeqRMETA and UNCeqRDNA . As another
DNA-only control, a leading (45) DNA-WES mutation
caller from Illumina, Strelka (17), was run on the same
DNA-WES. Strelka exhibited inferior performance overall, smaller true positive rates at fixed false positive rates,
and never achieved the sensitivity of UNCeqRMETA or
UNCeqRDNA (Figure 2). Strelka had greater sensitivity than
UNCeqRMETA or UNCeqRDNA at the highest extreme of
specificity; however, at UNCeqR’s minimum false positive
rate, Strelka’s sensitivity was only ∼70% of either UNCeqR model. Providing another DNA-only control, previously published mutations of this cohort made by heterogeneous pipelines (4,6,9,15–16) had reduced sensitivity
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performance over UNCeqRDNA (difference in area under the
curve, P < 0.01); in other words, UNCeqRMETA achieved
a greater true positive rate (greater sensitivity) at the same
false positive rate (same specificity) than UNCeqRDNA . In
simulations with a 20% MAF (Figure 1B), UNCeqRMETA
continued to be superior to UNCeqRDNA (difference in area
under the curve, P < 0.01) although the gain in 20% MAF
simulations was less (roughly 50% less) than the gain in 10%
MAF simulations. This demonstrates that adding RNA-seq
improved sensitivity, particularly when the mutation signal, that is MAF, was low. UNCeqRMETA and UNCeqRDNA
had large and clear superior performance to UNCeqRRNA ,
which incurred false positives at a higher rate. Alternative
ways to integrate RNA and DNA (taking the union or intersection of UNCeqRDNA and UNCeqRRNA ) were both inferior to UNCeqRMETA (Supplementary Figure S3). Therefore, in simulation, UNCeqRMETA achieved superior performance over UNCeqRDNA , with the largest gains occurring in
mutations with low MAF.

e107 Nucleic Acids Research, 2014
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Increased mutation signal in RNA-seq

than UNCeqRMETA and UNCeqRDNA at the same false positive rate (256 false positives). At this false positive rate, indel mutation detections were rare in all models (maximum
1.7%) with UNCeqRMETA and UNCeqRDNA having no significant difference in indel precision (number of true positives divided by the sum of false positives and true positives, 92 and 96%, respectively) but both having greater indel precision than Strelka (83%) and previously published
mutations (82%) (proportions test, P < 0.001). Taking the
union or intersection of UNCeqRDNA and UNCeqRRNA
had higher false positive rates and inferior performance
than UNCeqRMETA or UNCeqRDNA (Supplementary Figure S4A). Integrating Strelka with an RNA-seq mutation
detector, SNVmix, did not result in superior performance
versus Strelka, UNCeqRDNA or UNCeqRMETA (Supplementary Figure S4A). Providing a separate source of validation,
UNCeqRMETA detected nearly all mutations that were published as validated by targeted resequencing within this cohort (up to 97%, depending on the model threshold; Supplementary Figure S5). Repeating this analysis with a slightly
increased true positivity definition, minimum two confirming tumor WGS DNA reads, maintained all findings listed
above (Supplementary Figure S4B).
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Figure 2. Validation of mutation detection by whole genome sequencing. The number of true positives and false positives of mutation detection
models are plotted as step functions. At fixed false positive totals (250, 500
or 1000), each pair of models was compared for differences in number of
true positives (*). The published mutation set (4,6) did not include mutation rankings and was not amenable to rank-based statistical analysis.

To analyze integrated mutation detection across larger cohorts, UNCeqR was applied to the lung and breast triplet
cohorts (n = 871) and using model thresholds with the
same empirically estimated specificity (500 false positives
in DNA-WGS validation sequencing, marked as triangle
point in Figure 2, UNCeqRMETA P-value ≤ 1.1 × 10−9 ,
UNCeqRDNA P-value ≤ 9.3 × 10−9 ). About half (49%)
of UNCeqRMETA mutations had no RNA evidence and
were based only on DNA evidence. Surprisingly among
UNCeqRMETA expressed somatic mutations (those with
RNA and DNA mutant read evidence), the MAF in RNA
was often significantly greater than in DNA (lung: 21%
of expressed mutations, breast: 17%, fdr < 0.05) (Figure
3A and Supplementary Figure S6A). This increase was
often >2-fold (lung: 12% of expressed mutations, breast:
11%). In contrast, DNA MAF was significantly greater
than RNA MAF at much lower frequency (lung: 2% of
expressed mutations, breast: 3%, fdr < 0.05). As a control, germline variants were detected in germline DNAWES and patient-matched germline RNA-seq relative to
the reference genome by UNCeqRMETA under the same settings as somatic mutation detection (Figure 3B and Supplementary Figure S6B). In contrast to expressed somatic mutations, expressed germline variants displayed rare significant differences in allele fraction (RNA greater than DNA:
lung: 0.8%, breast: 0.7%; DNA > RNA: lung 0.1%, breast:
0.3%). Therefore, the prevalent, increased mutation signal
in RNA-seq was cancer-specific.
In addition to the genome-wide phenomenon, the increased mutation signal in RNA versus DNA might additionally be frequent in cancer driver genes. Lung and
breast cancer’s driver genes (4,6) with at least 10% prevalence were analyzed for differences in RNA to DNA MAF
across all mutations, whether expressed or not. Eight driver
genes had significantly different MAF between DNA and
RNA (Wilcoxon signed rank test, fdr < 0.05; Figure 3C).
All of these genes had greater median MAF in RNA than
in DNA, including an oncogene, PIK3CA and tumor suppressors, such as TP53. The TP53 MAF distributions of
lung and breast cancer had remarkable similarities (Figure 3D), in that nonsynonymous and splice site mutations
had extremely high RNA MAF relative to DNA MAF, often 2-fold greater. Stop-gain and frameshift mutations in
TP53 had greater MAF in DNA versus RNA but these decreases were less common and had a smaller magnitude in
MAF difference. The TP53 results extend an earlier report
in lung cancer using direct sequencing of TP53 RNA transcripts which found mutant transcript predominant expression (46). In summary, expressed mutations tend to have
larger mutation signal in RNA than in DNA. Importantly,
this effect was common among driver genes, suggesting that
integrating DNA and RNA for mutation detection provides
the best opportunity to identify cancer causing mutations.
Because DNA copy number can affect the quantity of
tumor versus germline DNA at a locus, tumor DNA copy
number alterations were compared among mutations with
a significantly greater MAF in RNA versus DNA and vice
versa. Mutations with greater MAF in RNA exhibited a
small (roughly 5%) relative increase in DNA copy number

PAGE 7 OF 12

Nucleic Acids Research, 2014 e107

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on August 19, 2014

Figure 3. Mutation signal in RNA versus DNA. Mutant allele fraction distributions of UNCeqRMETA expressed mutations from the lung triplet cohort
tumor sequencing (A). Germline variant allele fraction distributions of expressed germline variants from lung quadruplet cohort germline sequencing
(B). Diagonal lines indicate equal allelic fraction between DNA and RNA, with points above the diagonal having greater allelic fraction in RNA, below
the diagonal greater allelic fraction in DNA. Breast cancer somatic mutation and germline allele distributions in Supplementary Figure S6. Distributions
of MAF difference among driver genes having a significant difference in MAF over all mutations (C). MAF distributions for all TP53 UNCeqRMETA
mutations, expressed and unexpressed (C and D).
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deletions (Supplementary Figure S7), suggesting that RNA
is beneficial to detect mutations in regions of genome deletion. MAF differences in TP53 mutations did not associate
with either DNA amplifications or DNA deletions (Supplementary Figure S7).
Large gains in low purity tumors

Increased mutation rates of driver and therapeuticallytargeted genes
To determine if UNCeqRMETA made new mutation discoveries in patients’ tumor genomes, UNCeqRMETA mutations were compared to previously published patient mutation profiles on the triplet cohorts (4,6). Specifically,
tumors’ non-silent mutations (those that change protein
sequence and can contribute to cancer development) of
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Because low tumor purity (caused by normal contamination and multiple clones) can affect mutation detection
(2,8), the outcome of integrating RNA-seq and DNA-WES
in mutation detection was compared among tumors by their
purity. The rate of mutation gain after adding RNA-seq
to DNA-WES was non-uniform both in the breast and
lung triplet cohorts, such that the greatest gains occurred
in tumors having the lowest purity. Specifically, tumors’ total mutation ratio (the number of mutations detected by
UNCeqRMETA over UNCeqRDNA ) had significant negative
correlation with tumor purity in both lung and breast cancer (Figure 4A). Mutation gains were largest among tumors
with purity <40%. In addition, tumors’ average difference
in mutation signal between RNA and DNA (the mean difference of RNA MAF to DNA MAF across all expressed
UNCeqRMETA mutations) also had significant negative correlation with tumor purity both in lung and breast cancer (Figure 4B). Therefore, tumors with low purity had the
largest RNA-seq mutation signal and gained the most new
mutations after incorporation of RNA-seq evidence.
Examples of low purity tumors with large mutation gains
include a low purity breast tumor that had 1.8 total mutation ratio and a mean 0.18 difference in mutation signal
among expressed mutations. Two of this tumor’s mutations
with much larger signal in RNA than DNA occurred in
PIK3CA (p.H1047R) and GATA3 (p.S412fs) (Figure 4C).
These mutations occur in major mutational hotspots (47)
and are also characteristic molecular drivers for the Luminal A expression subtype (6,48) of which this tumor is
a member. Incorporation of RNA-seq evidence was essential to identify these two driving mutations; e.g. there was
only 1 DNA read with the PIK3CA mutation but 29 mutant reads in RNA-seq (Figure 5). An example lung tumor
had a 1.2 total mutation ratio and an average 0.22 difference
in mutation signal among expressed mutations including
CDKN2A (p.H98P) and TP53 (p.R273H) which exhibited
very large RNA MAF (at 100 and 84%) relative to DNA
MAF (at 43 and 46%) (Figure 4D). These PIK3CA, GATA3
and TP53 mutations were not detected by earlier studies utilizing DNA-WES alone (4,6), emphasizing the advantage of
RNA integration. In summary, the addition of RNA-seq to
DNA-WES substantially boosted mutation sensitivity for
low purity tumors.
Figure 4. Tumor purity effects on mutation detection. Lines summarize
breast and lung triplet cohorts, displaying total mutation ratios (A) or
mean mutant allele fraction difference within expressed mutations (B)
among tumors, binned by tumor purity quintile and plotted at midpoint.
Pearson’s correlation tests compared the association of mutation ratio and
MAF associations among triplet cohort tumors (P). MAF distributions
from two exemplar low purity tumors’ mutations (C and D). Diagonal lines
indicate equal MAF in DNA-WES and RNA-seq, with mutations above
the diagonal having greater MAF in RNA, below the diagonal greater
MAF in DNA. Unexpressed mutations are marked along the horizontal
axes in (C and D).
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DISCUSSION

Figure 5. Example of somatic mutation only detectable by RNA and DNA
integration. Mutation detected by UNCeqRMETA P = 1e-16. Read alignment display from integrative genomics viewer (43) for a low purity breast
tumor at the major mutational hotspot of PIK3CA (47).

UNCeqRMETA that were novel compared to published profiles were tabulated within genes known to be relevant in
cancer development (187 genes, from the Cancer Gene Census (49) and published driver genes (4,6)). Five hundred and
sixty-seven novel mutations were detected covering 67% of
these cancer-relevant genes. 69% of these novel mutations
had DNA-WES and RNA-seq evidence, indicating that the
addition of RNA contributed to the vast majority of these
novel mutations. Grouped by patients, 44% of patients’ tu-

Herein, we sought to determine if adding patient-matched
RNA-seq to DNA-WES would improve somatic mutation
detection. To this end, we developed UNCeqR, a first-ofits-kind method, that integrates RNA-seq and DNA-WES
to detect somatic mutations. By simulation and validation
in whole genome sequencing, the UNCeqRMETA model that
integrates DNA and RNA had significantly superior performance to models based on DNA alone (UNCeqRDNA ,
Strelka and published mutation profiles). Then, we applied
UNCeqR to large breast and lung cohorts (n = 871) and analyzed their integrated RNA and DNA mutations, resulting
in several novel characterizations of tumor genomics.
We report for the first time a remarkable finding that low
purity tumors experience the largest gains in total mutations and in mutation signal (MAF) when adding RNA-seq
to DNA-WES. Also, we originally report that that MAF

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on August 19, 2014

mors had an increase of at least one new mutation in this
cancer-relevant gene set, and among patient tumors with
zero published mutations in this gene set, 42% had at least
one new mutation discovered by UNCeqRMETA . Grouped
by gene, many of these novel mutations comprised large
gains in absolute counts and in percent increase (Figure 6A
and B), including MAP3K1 and GATA3 in breast cancer,
and NOTCH2 and CDKN2A in lung cancer. These gains
spanned all nucleotide mutation types (substitution, insertion and deletion) and protein coding impacts; for instance,
novel GATA3 mutations had abundant novel frameshift
insertion, frameshift deletion, non-synonymous and nonsense mutations (Supplementary Figure S8). Notably, mutation rates for genes targeted by drugs were increased by
UNCeqRMETA , specifically, PIK3CA, FGFR2 and ERBB2.
Therefore, UNCeqRMETA largely advanced published, stateof-the-art mutation profiles with cancer-relevant mutations
by utilizing the integration of RNA-seq and DNA-WES.
Breast cancer subtypes (48) were previously found to have
distinct rates of mutations across four genes (TP53, GATA3,
MAP3K1 and PIK3CA) and, in combination with other evidence such as pathway alterations, are understood to be
driven by their distinct somatic alterations (6). Across these
four genes, novel mutations detected by UNCeqRMETA occurred most frequently in tumors of the same expression
subtype as had been previously reported. Specifically, the
greatest number of novel mutations occurred in the following subtypes: TP53 in Basal, MAP3K1 in Luminal A,
PIK3CA in Luminal A and GATA3 in Luminal A and Luminal B (Figure 6C). In lung cancer, there were appreciable
increases in NOTCH1 and NOTCH2. The largest numbers
of novel UNCeqRMETA NOTCH1 and NOTCH2 mutations
occurred in different lung cancer expression subtypes (50)
of Classical and Basal, respectively (Figure 6D). Combining novel UNCeqR non-silent mutations with those previously reported, both of these genes now had significant association with expression subtype (NOTCH1 Fisher’s test
P < 0.02; NOTCH2 Fisher’s test P < 0.03). Therefore, the
advance of UNCeqRMETA over published mutation profiles
included new subtype-specific driving mutations, new putative subtype-specific driver genes, and new patients with
mutations in driver genes.

e107 Nucleic Acids Research, 2014

PAGE 10 OF 12

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on August 19, 2014

Figure 6. Novel mutation discoveries in cancer-relevant genes. Increases in mutation absolute count versus relative increase are displayed for selected genes
(A and B). Percentage increase is the number of novel UNCeqRMETA mutations over the number of published mutations (4,6)for a gene. Absolute counts
for select genes among breast (C) and lung (D) cancer expression subtypes.
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UNCeqRMETA increases mutation detection performance
and was extremely beneficial for low purity tumors.
AVAILABILITY
UNCeqR software is available at http://lbg.med.unc.edu/
tools/unceqr. UNCeqR mutation detections for the lung
and breast cohorts are available at https://tcga-data-secure.
nci.nih.gov/tcgafiles/tcga4yeo/tumor/ and http://lbg.med.
unc.edu/tools/unceqr.
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